Literature DB >> 311815

The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice.

K J Weinhold, L T Goldstein, E F Wheelock.   

Abstract

Subcutaneous implantation of DBA/2-derived L5178Y cells into DBA/2 mice followed 10 d later by nodule excision protected 100% of mice from the rapid outgrowth of an intraperitoneal challenge of L5178Y cells given 7 d postexcision. Challenged mice remained clinically normal for 48--250 d before onset of an ultimately fatal tumor outgrowth. The numbers of L5178Y cells in the peritoneal cavity increased logarithmically for 4 d after challenge and then declined to low but detectable levels which persisted throughout the clinically normal period. Cells active in 18-h in vitro cytolytic assays against 51Cr-labeled L5178Y target cells were found in the peritoneal cavity. The effector cells were determined to be Thy1.2 positive. Their activity was tumor specific and reached peak levels 4 d after tumor challenge and then gradually declined to undectable levels during the following 70 d. Tumor emergence occurred most frequently during the period when CMC activity was no longer demonstrable in the remaining clinically normal mice. A transient peak of low level cytophilic antitumor antibody was detected about 30 d after tumor cell challenge. The temporal associations between the numbers of tumor cells and the levels of cell-mediated lysis against L5178Y cells indicate the importance of the cell-mediated cytolysis response in limiting initial tumor outgrowth and suggest its role as one of the factors responsible for long-term tumor suppression during tumor dormancy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 311815      PMCID: PMC2184833          DOI: 10.1084/jem.149.3.732

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  33 in total

1.  Experimental evidence in support of the dormant tumor cell.

Authors:  B FISHER; E R FISHER
Journal:  Science       Date:  1959-10-09       Impact factor: 47.728

2.  Immunogenicity of tumor antigens.

Authors:  R B Herberman; D A Campbell; R K Oldham; G D Bonnard; C C Ting; H T Holden; M Glaser; J Djeu; R Oehler
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

3.  The dormant cancer cell.

Authors:  G HADFIELD
Journal:  Br Med J       Date:  1954-09-11

4.  Chronic infusion of tritiated thymidine into mice with tumors.

Authors:  M L MENDELSOHN
Journal:  Science       Date:  1962-01-19       Impact factor: 47.728

5.  Characterization of suppressive immunoglobulin-binding factor (IBF). I. Production of IBF by a theta-positive lymphoma (L-5178-Y).

Authors:  W H Fridman; A Guimezanes; R H Gisler
Journal:  J Immunol       Date:  1977-10       Impact factor: 5.422

Review 6.  Duration of the dormant state in an established cell line of human hematopoietic cells.

Authors:  B D Clarkson; J Fried; T C Chou; A Strife; R Ferguson; S Sullivan; T Kitahara; A Oyama
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

Review 7.  A new concept of tissue and tumor cell proliferation.

Authors:  S Gelfant
Journal:  Cancer Res       Date:  1977-11       Impact factor: 12.701

8.  Inflammatory oncotaxis.

Authors:  R P DerHagopian; E V Sugarbaker; A Ketcham
Journal:  JAMA       Date:  1978-07-28       Impact factor: 56.272

9.  The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination.

Authors:  K J Weinhold; D A Miller; E F Wheelock
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

10.  T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites.

Authors:  R J North; D P Kirstein
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

View more
  18 in total

Review 1.  Mechanisms of Cancer Cell Dormancy--Another Hallmark of Cancer?

Authors:  Albert C Yeh; Sridhar Ramaswamy
Journal:  Cancer Res       Date:  2015-09-09       Impact factor: 12.701

2.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis.

Authors:  V A Kuznetsov; I A Makalkin; M A Taylor; A S Perelson
Journal:  Bull Math Biol       Date:  1994-03       Impact factor: 1.758

Review 3.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

4.  Establishment and control of the L5178Y-cell tumor dormant state in DBA/2 mice.

Authors:  E F Wheelock; M K Robinson; G A Truitt
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

5.  Cytotoxic T lymphocytes in DBA/2 mice harboring L5178Y cells in a tumor-dormant state.

Authors:  M A Marsili; M K Robinson; G A Truitt; E F Wheelock
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.

Authors:  Ilia N Buhtoiarov; Alexander L Rakhmilevich; Lewis L Lanier; Erik A Ranheim; Paul M Sondel
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

Review 7.  The dormant cancer cell life cycle.

Authors:  Tri Giang Phan; Peter I Croucher
Journal:  Nat Rev Cancer       Date:  2020-06-02       Impact factor: 60.716

8.  Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state.

Authors:  Michele W L Teng; Matthew D Vesely; Helene Duret; Nicole McLaughlin; Jennifer E Towne; Robert D Schreiber; Mark J Smyth
Journal:  Cancer Res       Date:  2012-08-06       Impact factor: 12.701

9.  Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications.

Authors:  Xin Dong; Hui Xue; Fan Mo; Yen-Yi Lin; Dong Lin; Nelson K Y Wong; Yingqiang Sun; Scott Wilkinson; Anson T Ku; Jun Hao; Xinpei Ci; Rebecca Wu; Anne Haegert; Rebecca Silver; Mary-Ellen Taplin; Steven P Balk; Joshi J Alumkal; Adam G Sowalsky; Martin Gleave; Colin Collins; Yuzhuo Wang
Journal:  Mol Cancer Res       Date:  2022-05-04       Impact factor: 6.333

10.  Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.

Authors:  Timothy Kottke; Nicolas Boisgerault; Rosa Maria Diaz; Oliver Donnelly; Diana Rommelfanger-Konkol; Jose Pulido; Jill Thompson; Debabrata Mukhopadhyay; Roger Kaspar; Matt Coffey; Hardev Pandha; Alan Melcher; Kevin Harrington; Peter Selby; Richard Vile
Journal:  Nat Med       Date:  2013-11-17       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.